Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Am J Kidney Dis. 2015 Sep;66(3):450-8. doi: 10.1053/j.ajkd.2015.03.032. Epub 2015 May 16.
BACKGROUND: Low serum bicarbonate level has been reported to be an independent predictor of kidney function decline and mortality in patients with chronic kidney disease. Mechanisms underlying low serum bicarbonate levels may differ in patients with and without diabetes. We aimed to specifically investigate the association of serum bicarbonate level with kidney disease progression and cardiovascular outcome in a cohort of patients with type 2 diabetes and nephropathy. STUDY DESIGN: Post hoc analysis of 2 multicenter randomized controlled trials. SETTING & PARTICIPANTS: 2,628 adults with type 2 diabetes and nephropathy. FACTOR: Serum bicarbonate level. OUTCOMES: Incidence of: (1) end-stage renal disease (ESRD), (2) ESRD or doubling of serum creatinine level, (3) all-cause mortality, (4) cardiovascular events (fatal/nonfatal stroke/myocardial infarction), and (5) heart failure. MEASUREMENTS: Serum bicarbonate was measured at baseline as total carbon dioxide. Associations of baseline serum bicarbonate level with end points were investigated using Cox regression models. Serum bicarbonate levels were studied as a continuous variable and stratified in quartiles. Follow-up was 2.8±1.0 (SD) years. RESULTS: Cox regression analyses showed that serum bicarbonate level had inverse associations with incident ESRD (HR, 0.91; 95% CI, 0.89-0.93; P<0.001) and incidence of the combined end point of ESRD or serum creatinine doubling (HR, 0.94; 95% CI, 0.92-0.96; P<0.001). These associations were independent of age, sex, and cardiovascular risk factors, but disappeared after adjustment for baseline estimated glomerular filtration rate (all P>0.05). Analysis of bicarbonate quartiles showed similar results for the quartile with the lowest bicarbonate (≤21 mEq/L) versus the quartile with normal bicarbonate levels (24-26 mEq/L). There was no association of bicarbonate level with cardiovascular events and heart failure. LIMITATIONS: Post hoc analysis and single measurement of serum bicarbonate. CONCLUSIONS: In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.
背景:已有研究表明,血清碳酸氢盐水平较低是慢性肾脏病患者肾功能下降和死亡的独立预测因子。在有或没有糖尿病的患者中,导致低血清碳酸氢盐水平的机制可能不同。我们旨在专门研究血清碳酸氢盐水平与患有 2 型糖尿病和肾病的患者的肾脏疾病进展和心血管结局的相关性。 研究设计:两项多中心随机对照试验的事后分析。 设置和参与者:2628 名患有 2 型糖尿病和肾病的成年人。 因素:血清碳酸氢盐水平。 结局:终末期肾病(ESRD)、ESRD 或血清肌酐水平翻倍、全因死亡率、心血管事件(致死性/非致死性卒中/心肌梗死)和心力衰竭的发生率。 测量:在基线时,血清碳酸氢盐作为总二氧化碳进行测量。使用 Cox 回归模型研究基线血清碳酸氢盐水平与终点的相关性。血清碳酸氢盐水平作为连续变量进行研究,并分层为四分位。随访时间为 2.8±1.0(标准差)年。 结果:Cox 回归分析显示,血清碳酸氢盐水平与 ESRD 事件呈负相关(HR,0.91;95%CI,0.89-0.93;P<0.001)和 ESRD 或血清肌酐翻倍的联合终点发生率呈负相关(HR,0.94;95%CI,0.92-0.96;P<0.001)。这些关联独立于年龄、性别和心血管危险因素,但在调整基线估计肾小球滤过率后消失(所有 P>0.05)。对碳酸氢盐四分位数的分析显示,最低碳酸氢盐(≤21 mEq/L)与正常碳酸氢盐水平(24-26 mEq/L)四分位数的结果相似。碳酸氢盐水平与心血管事件和心力衰竭无关。 局限性:事后分析和血清碳酸氢盐的单次测量。 结论:在患有 2 型糖尿病和肾病的患者队列中,血清碳酸氢盐水平与肾脏疾病终点的相关性在调整估计肾小球滤过率后并未保留,这与非糖尿病人群的早期研究结果相反。
Clin J Am Soc Nephrol. 2017-9-18
Arch Intern Med. 2003-7-14
Clin J Am Soc Nephrol. 2015-12-7
Cochrane Database Syst Rev. 2024-4-29
Biosensors (Basel). 2022-10-21
J Clin Endocrinol Metab. 2022-11-23